Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery
Summary
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts. Schrödinger’s computational platform combines physics-based modeling and machine learning to enable chemists to predict the potency of a molecule binding to a target protein. Schrödinger’s platform will be used by AstraZeneca’s medicinal and computational chemists to help improve the design of compounds to identify potential new therapeutic candidates. To ensure a comprehensive knowledge transfer, Schrödinger’s team will work closely and share best practices with AstraZeneca to help integrate the platform into their drug discovery workflow. Garry Pairaudeau, Global Chemistry Lead, R&D, AstraZeneca, commented: “ Our strategic goal is to transform drug design using innovative digital technologies.
Classifications
AskAI Classifications
LabelsLinked Companies
